CoChat

Overcoming the Variability of iPSCs in the Manufacturing of Cell-Based Therapies

Open access
Nath, Suman C., Menendez, Laura, Friedrich Ben-Nun, Inbar · 2023 · International Journal of Molecular Sciences

The DOI matches its Crossref record; 85 of the 86 references it cites were found in a registry or an index; 88 of the 124 sources its claims cite were checked for support.

Abstract

Various factors are known to contribute to the diversity of human induced pluripotent stem cells (hiPSCs). Among these are the donor’s genetic background and family history, the somatic cell source, the iPSC reprogramming method, and the culture system of choice. Moreover, variability is seen even in iPSC clones, generated in a single reprogramming event, where the donor, somatic cell type, and reprogramming platform are the same. The diversity seen in iPSC lines often translates to epigenetic differences, as well as to differences in the expansion rate, iPSC line culture robustness, and their ability to differentiate into specific cell types. As such, the diversity of iPSCs presents a hurdle to standardizing iPSC-based cell therapy manufacturing. In this review, we will expand on the various factors that impact iPSC diversity and the strategies and tools that could be taken by the industry to overcome the differences amongst various iPSC lines, therefore enabling robust and reproducible iPSC-based cell therapy manufacturing processes.

Overview

CoChat Summary

TL;DR

This review argues that human induced pluripotent stem cell (hiPSC) diversity—arising from donor genetics, somatic cell source, reprogramming method, culture conditions, and even interclonal variation—is a central hurdle to standardizing iPSC-based cell therapy manufacturing. It surveys strategies such as defined media, automation, 3D bioreactor culture, and analytics to make manufacturing more robust and reproducible.

Key findings

  • iPSC lines differ due to donor genetic background, somatic cell type, reprogramming method, and culture system; variability persists even among clones from a single reprogramming event (same donor, cell type, and platform).
  • Donor effects: in a study of 194 healthy donors (101 female, 93 male), transcriptomic and proteomic profiling showed variability in CD41 and CD42a expression in iPSC-derived megakaryocytes, with differences by sex and race but not age. Reprogramming efficiency of adult fibroblasts was lower than newborn fibroblasts with a four-factor synthetic self-replicating RNA method, and could be improved by adding a fifth transcription factor.
  • Somatic cell source: comparing 696 hiPSCs and daughter subclones, about 72% had genomic heterogeneity due to UV-related damage, indicating skin fibroblast-derived iPSCs harbor more pre-existing mutations than blood-derived iPSCs.
  • Reprogramming method: chemical reprogramming of human somatic cells initially took 50 days with 0.2–2.5% efficiency, later optimized to 16 days with small-molecule boosters. Culture conditions (enzymatic vs. mechanical passaging, feeder-free vs. feeder-dependent) affect growth rate, genetic instability, and OCT4-positive cells in teratomas.
  • Of 19 published hiPSC therapeutic trials cited (end of 2021), 15 (79%) were allogeneic and 4 autologous.

Methods

This is a narrative review; no primary data were generated. It synthesizes published literature on iPSC variability and manufacturing standardization, citing specific studies (e.g., Kammers et al., Yoshioka et al., Rouhani et al., Laurent et al., Mayshar et al., Paull et al., Bando et al., Konagaya et al., Tristan et al., Elanzew et al., Pandey et al.) to illustrate donor, somatic cell, reprogramming, culture, automation, 3D culture, and analytics considerations.

Limitations

The paper does not present a formal limitations section. Evident from the text: it is a review without systematic search or meta-analysis, so selection of cited studies may be non-exhaustive; several cited findings (e.g., donor sex/race effects, UV-related heterogeneity) come from individual studies whose generalizability is not assessed; and the authors note that automated systems in 2D and 3D for combined iPSC generation, expansion, and differentiation "has remained unexplored," and that industrial manufacturing has not yet fully adopted an integrated automated system.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/ijms242316929

Cites

85 of 85 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Diversity of iPSCs in cell therapy applications. Common causes of iPSC diversity are the source of the starting cells, reprogramming methods, and culture conditions. The effect of this diversity can, in turn, influence the differentiation potential of the generated iPSCs and, therefore, the final outcome of the therapy.
Figure 1 Diversity of iPSCs in cell therapy applications. Common causes of iPSC diversity are the source of the starting cells, reprogramming methods, and culture conditions. The effect of this diversity can, in turn, influence the differentiation potential of the generated iPSCs and, therefore, the final outcome of the therapy.CC BY · PubMed Central
Figure 2 Advantages of automated systems.
Figure 2 Advantages of automated systems.CC BY · PubMed Central

Verification

Claims the paper makes

52 Valid · 3 Not valid · 13 Not checked · 17 Own results and interpretations

42 more claims · 28 with their cited sources checked

Create a free account to see all 85 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 26
  • Probably not a substantial claim. 16

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Cited by

See all 35

Metadata

Authors
Nath, S. C., Menendez, L., & Friedrich Ben-Nun, I.
Affiliations
  • Lonza (United States) (US)
  • Cell Therapy Process Department, Lonza Inc., Houston, TX 77047, USA
  • Cell Therapy Research and Development, Lonza Inc., Rockville, MD 20850, USA
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2023-11-29
Volume
24
Issue
23
Pages
16929
ISSN
1422-0067 (ISSN-L)
OpenAlex
W4389137472
Cited by
35
References
86
Citations by year
2026: 19 · 2025: 10 · 2024: 6
FWCI
0.86
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
Keywords
induced pluripotent stem cells, cell therapy manufacturing, epigenetic variation, differentiation potential
MeSH terms
Cell Differentiation, Humans, Epigenesis, Genetic, Induced Pluripotent Stem Cells, Cell- and Tissue-Based Therapy, Cellular Reprogramming

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.